The method for production of the stable pharmaceutical form of paclitaxel as an anticancer drug consists in dissolution of crystalline paclitaxel in a neutral organic solvent selected from the group comprising acetonitrile, dioxane, ethanol, or a mixture of those solvents, with possible addition of water, providing that the content of individual solvents in the mixture is in the range of 5 % to 95 %, while the content of water is in the range of 0 to 60 %； the resulting solution is possibly filtered, frozen, and solvents are removed by sublimation under reduced pressure, at a low temperature, and thereafter the preparation is possibly distributed into doses in conditions assuring its sterility.The method for production of the stable pharmaceutical form of paclitaxel as an anticancer drug consists in dissolution of crystalline paclitaxel in a neutral organic solvent selected from the group comprising acetonitrile, dioxane, ethanol, or a mixture of those solvents, with possible addition of water, providing that the content of individual solvents in the mixture is in the range of 5 % to 95 %, while the content of water is in the range of 0 to 60 %； the resulting solution is possibly filtered, frozen, and solvents are removed by sublimation under reduced pressure, at a low temperature, and thereafter the preparation is possibly distributed into doses in conditions assuring its sterility.
